Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.46 |
| ▸ | NPY1R | P25929 | 6/20 | 0.46 |
| ▸ | NPY2R | P49146 | 4/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.46 |
| ▸ | FNTA | P49354 | 5/20 | 0.46 |
| ▸ | FNTB | P49356 | 5/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30787014 | 0.98 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL30045207 | 0.95 | FNTA (0.47) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL29482503 | 0.95 | FNTA (0.51) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL29511195 | 0.95 | FNTA (0.51) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL29511116 | 0.92 | FNTA (0.47) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL30725662 | 0.91 | APLNR (0.45) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL31620050 | 0.90 | CTSL (0.46) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL29476479 | 0.90 | FNTA (0.49) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL31252942 | 0.90 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL29461968 | 0.90 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | claimed |
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | claimed |
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | claimed |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2026-03-26 | — | — | US | disclosed |
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | MC4R, NPY4R, MC3R | NPY4R 2/4885NPY1R 8/4885NPY2R 7/4885 |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | THRB, MC1R, MC5R | NPY4R 41/4885NPY1R 9/4885NPY2R 12/4885 |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | MC3R, MC1R, MC5R | NPY4R 25/4885NPY1R 12/4885NPY2R 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.